A 58-year-old man presents to his physician for routine follow-up. He has compensated cirrhosis due to chronic hepatitis C infection that was successfully treated 4 years ago with direct-acting antiviral therapy. He has no history of ascites, variceal bleeding, hepatic encephalopathy, or hepatocellular carcinoma. His medications include propranolol for portal hypertension. He feels well and denies abdominal pain, weight loss, jaundice, or gastrointestinal bleeding. Vital signs are normal. Physical examination demonstrates mild splenomegaly but is otherwise unremarkable.
Laboratory studies reveal the following:
Which of the following is the most appropriate strategy for hepatocellular carcinoma (HCC) surveillance?
The correct answer is:
A) Abdominal ultrasound every 6 months
This patient has compensated cirrhosis, which remains the single most important risk factor for hepatocellular carcinoma (HCC). Although his hepatitis C infection has been successfully treated, the presence of established cirrhosis continues to place him at elevated risk for developing HCC. Therefore, ongoing surveillance is recommended.
HCC often develops silently and may remain asymptomatic until advanced stages. Surveillance aims to identify tumors at an early stage when potentially curative treatments such as surgical resection, liver transplantation, or local ablative therapy are still possible. Multiple studies have demonstrated improved early detection rates and better outcomes with routine surveillance in high-risk populations.
Current recommendations call for surveillance with abdominal ultrasound every 6 months in most patients with cirrhosis. Some centers also incorporate serum alpha-fetoprotein (AFP), but ultrasound remains the cornerstone of surveillance and is the modality most commonly tested on Step 2.
A common board trap is assuming that successful treatment of hepatitis C eliminates cancer risk. While antiviral therapy substantially reduces the risk of HCC, patients with established cirrhosis continue to require surveillance because their risk remains significantly elevated compared with the general population.
Answer choice B: Annual CT scan of the abdomen, is incorrect.
CT scanning is not routinely used for surveillance because it is more expensive, exposes patients to radiation, and has not replaced ultrasound as the preferred screening modality. CT is generally used when surveillance imaging identifies a suspicious lesion.
Answer choice C: Colonoscopy every 5 years, is incorrect.
Colonoscopy may be appropriate for colorectal cancer screening in some patients, but it is not a strategy for HCC surveillance and does not address this patient’s greatest malignancy risk.
Answer choice D: No surveillance is necessary because hepatitis C has been cured, is incorrect.
This is a classic Step 2 trap. Viral eradication decreases but does not eliminate HCC risk in patients with established cirrhosis. Surveillance should continue indefinitely.
Answer choice E: Serum alpha-fetoprotein measurement every 5 years, is incorrect.
AFP alone is insufficient for surveillance, and a 5-year interval would miss many early cancers. Ultrasound every 6 months is the recommended approach.
Key Learning Point
Patients with cirrhosis require ongoing hepatocellular carcinoma surveillance with abdominal ultrasound every 6 months, even if the underlying cause of liver disease, such as hepatitis C infection, has been successfully treated.
